EYPT
Price
$18.29
Change
+$0.03 (+0.16%)
Updated
Dec 26 closing price
Capitalization
1.51B
67 days until earnings call
Intraday BUY SELL Signals
IDYA
Price
$35.20
Change
-$0.48 (-1.35%)
Updated
Dec 26 closing price
Capitalization
3.09B
93 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EYPT vs IDYA

Header iconEYPT vs IDYA Comparison
Open Charts EYPT vs IDYABanner chart's image
EyePoint
Price$18.29
Change+$0.03 (+0.16%)
Volume$821.95K
Capitalization1.51B
IDEAYA Biosciences
Price$35.20
Change-$0.48 (-1.35%)
Volume$449.45K
Capitalization3.09B
EYPT vs IDYA Comparison Chart in %
EYPT
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EYPT vs. IDYA commentary
Dec 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Buy and IDYA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 29, 2025
Stock price -- (EYPT: $18.29 vs. IDYA: $35.20)
Brand notoriety: EYPT and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 63% vs. IDYA: 46%
Market capitalization -- EYPT: $1.51B vs. IDYA: $3.09B
EYPT [@Biotechnology] is valued at $1.51B. IDYA’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 1 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than EYPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • EYPT’s TA Score: 4 bullish, 4 bearish.
  • IDYA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than IDYA.

Price Growth

EYPT (@Biotechnology) experienced а +4.93% price change this week, while IDYA (@Biotechnology) price change was +4.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

EYPT is expected to report earnings on Mar 05, 2026.

IDYA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($3.09B) has a higher market cap than EYPT($1.51B). EYPT YTD gains are higher at: 145.503 vs. IDYA (36.965). EYPT (-201.16M) and IDYA (-204.84M) have comparable annual earnings (EBITDA) . IDYA has more cash in the bank: 787M vs. EYPT (204M). EYPT has less debt than IDYA: EYPT (21.3M) vs IDYA (27.2M). IDYA has higher revenues than EYPT: IDYA (215M) vs EYPT (42.3M).
EYPTIDYAEYPT / IDYA
Capitalization1.51B3.09B49%
EBITDA-201.16M-204.84M98%
Gain YTD145.50336.965394%
P/E RatioN/AN/A-
Revenue42.3M215M20%
Total Cash204M787M26%
Total Debt21.3M27.2M78%
FUNDAMENTALS RATINGS
EYPT vs IDYA: Fundamental Ratings
EYPT
IDYA
OUTLOOK RATING
1..100
9269
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
6759
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
3640
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (27) in the null industry is somewhat better than the same rating for EYPT (71) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than EYPT’s over the last 12 months.

IDYA's Profit vs Risk Rating (59) in the null industry is in the same range as EYPT (67) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to EYPT’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as EYPT (99) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as IDYA (40) in the null industry. This means that EYPT’s stock grew similarly to IDYA’s over the last 12 months.

EYPT's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for IDYA (100) in the null industry. This means that EYPT’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTIDYA
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 11 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MINJX44.240.10
+0.23%
MFS International Intrinsic Value R6
PADEX23.000.02
+0.09%
Putnam Dynamic Asset Allocation Gr R5
MCIMX23.600.01
+0.04%
Victory Integrity Mid-Cap Value C
SEBLX30.47N/A
N/A
Touchstone Balanced A
LZUSX16.84-0.01
-0.06%
Lazard US Equity Focus Instl

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+0.16%
LYRA - EYPT
58%
Loosely correlated
+0.28%
ATHE - EYPT
54%
Loosely correlated
+2.42%
ERAS - EYPT
50%
Loosely correlated
+1.46%
OCUL - EYPT
50%
Loosely correlated
-1.18%
IDYA - EYPT
48%
Loosely correlated
-1.35%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.35%
NUVL - IDYA
59%
Loosely correlated
-1.57%
XENE - IDYA
58%
Loosely correlated
-0.38%
XNCR - IDYA
58%
Loosely correlated
-1.49%
CGON - IDYA
55%
Loosely correlated
-0.75%
IMTX - IDYA
54%
Loosely correlated
-1.45%
More